MBAI:NASDAQCheck-Cap Ltd. Analysis
Data as of 2026-04-16 - not real-time
Latest Price
Risk Level: High
Executive Summary
Check‑Cap Ltd. (MBAI) is trading at $1.73, well above its DCF‑derived fair value of roughly $0.28, indicating a significant overvaluation. The stock sits just above its 20‑day SMA ($1.68) and 50‑day SMA ($1.70) with a neutral trend, while the MACD shows a bullish crossover (MACD line positive vs. signal negative) and the RSI hovers around 51, suggesting neither strong overbought nor oversold pressure. Volatility is extreme at ~81% over the past 30 days and beta exceeds 1.6, underscoring heightened market sensitivity. Volume is increasing, providing some liquidity, but the market cap remains tiny (~$12.6 M) and the price is near the technical support of $1.48 with resistance around $2.19. The Fear & Greed Index reads “Extreme Greed,” reflecting speculative enthusiasm despite weak fundamentals.
Market Outlook
Short Term
< 1 yearKey Factors
- Technical overextension above fair value
- High volatility and beta increasing price risk
- Lack of revenue and negative cash flow
Medium Term
1–3 yearsKey Factors
- Potential clinical‑stage catalyst could shift valuation
- Continued cash burn limits upside without financing
- Technical support level provides downside buffer
Long Term
> 3 yearsKey Factors
- Innovative capsule‑based screening technology offers high upside
- Low debt and modest cash reserve could support runway with funding
- Success in regulatory approvals could unlock substantial value
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.